Health Remedies

FREE SHIPPING

On All Online Orders Over $100

Like Our Site?

Give us a +1

Cogniben - The First Multi-target Modulator for Cognitive Support

Date Posted July 24th, 2017
   
Cogniben - The First Multi-target Modulator for Cognitive Support

In partnership with TriNutraTM , LLC and Integrative Psychiatry, Inc., we at Health Remedies are pleased to announce the launch of CognibenTM,  a novel multi-target nutraceutical designed to give you:

  • Enhanced focus, concentration, and energy
  • Heightened mental alertness and clarity of thought
  • Optimal cognitive function

The synergistic combination and ratio of ingredients contained in Cogniben™ - PEA (phenylethylamine), Ginkgo biloba, and caffeine - are critical to its demonstrated effectiveness.  For instance, Ginkgo biloba, when combined with PEA, may significantly increase its bio-availability and clinical efficacy. 

Cogniben’s Patented Blend of Core Ingredients

·  Phenylethylamine (PEA) 

An amino acid that has been shown to modulate key brain chemicals:  serotonin, dopamine, acetylcholine, and norepinephrine.  Believed to optimize mental energy/stamina, concentration and attention, motivation, pleasure, and joy.

·  Ginkgo Biloba

A plant that improves blood flow to the brain and has documented cognitive benefits.

·  Caffeine

Cogniben contains approximately the same amount of caffeine as ½ cup of coffee.  The actions of caffeine at adenosine receptors might increase brain activity, alertness, and wakefulness. 

Safety, Tolerability, and Efficacy Demonstrated in Human Subjects

An impressive and distinct combination of synergistic ingredients, Cogniben, unlike most supplements, has data demonstrating its effectiveness in human subjects. 

This efficacy was demonstrated in a recent single-blind outpatient study in 10 adults (18 to 55 years of age) with symptoms of cognitive impairment.  Participants were titrated from half tablet of Cogniben™ daily, up to the maximally allowed dose of two tablets per day by the end of the Week Two. This dose was maintained for an additional 5 weeks. Subjects' symptoms, well-being, and improvements were assessed via questionnaires at baseline and subsequent visits.

A follow-up study involving 60 people is now under way.

Perhaps most impressive clinically is that when Cogniben works, it works quickly, as early as the first dose.  By regulating key brain circuits demonstrated by clinical research to be associated with cogitive functioning - dopamine, serotonin, acetylcholine, and norepinephrine - Cogniben addresses numerous cognitive domains immediately .*

*These statements have not been evaluated by the Food and Drug Administration.  Cogniben is not intended to diagnose, treat, cure, or prevent any disease. 


Back View All

Website Security Test